Abstract
Intestinal Behçet’s disease (BD) and Crohn’s disease (CD) present similar manifestations, but there are no specific diagnostic tests to differentiate them. We used a proteomic approach to discover novel diagnostic biomarkers specific to intestinal BD. Colon mucosa tissue samples were obtained from patients with intestinal BD or CD using colonoscopy-guided biopsy of the affected bowel. Peptides from seven intestinal BD and seven CD patients were extracted and labeled using tandem mass tag (TMT) reagents. The labeled peptides were identified and quantified using liquid chromatography-tandem mass spectrometry (LC–MS/MS). The proteins were further validated using immunohistochemical (IHC) analysis with tissue samples and an ELISA test with serum samples from 20 intestinal BD and 20 CD patients. Using TMT/LC–MS/MS-based proteomic quantification, we identified 39 proteins differentially expressed between intestinal BD and CD. Beta-2 glycoprotein 1 (APOH) and maltase-glucoamylase (MGAM) showed higher intensity in the IHC staining of intestinal BD tissues than in CD tissues. The serum MGAM level was higher in intestinal BD patients. Proteomic analysis revealed that some proteins were differentially expressed in patients with intestinal BD compared with those with CD. Differential MGAM expression in intestinal BD suggests its role as a potential novel diagnostic biomarker.
Highlights
Abbreviations BD Behçet’s disease CD Crohn’s disease IBD Inflammatory bowel disease tandem mass tag (TMT) Tandem mass tag liquid chromatography (LC)–MS Liquid chromatography-tandem mass spectrometry DAIBD Disease Activity Index for Intestinal Behçet’s Disease CDAI Crohn’s Disease Activity Index IHC Immunohistochemistry DAVID Database for Annotation, Visualization and Integrated Discovery MGAM Maltase-glucoamylase APOH Beta-2 glycoprotein 1 PLG Plasminogen interleukin 16 (IL16) Interleukin 16 serine/arginine-rich splicing factor 3 (SRSF3) Serine/arginine-rich splicing factor 3
The intestinal BD ulcer type was defined according to the Korean Inflammatory Bowel Disease study group, and the CD phenotype was defined according to the Montreal Classification[18,19]
Accurate diagnosis of intestinal BD and CD is important for establishing proper treatment plans and predicting disease prognosis[30]
Summary
Abbreviations BD Behçet’s disease CD Crohn’s disease IBD Inflammatory bowel disease TMT Tandem mass tag LC–MS Liquid chromatography-tandem mass spectrometry DAIBD Disease Activity Index for Intestinal Behçet’s Disease CDAI Crohn’s Disease Activity Index IHC Immunohistochemistry DAVID Database for Annotation, Visualization and Integrated Discovery MGAM Maltase-glucoamylase APOH Beta-2 glycoprotein 1 PLG Plasminogen IL16 Interleukin 16 SRSF3 Serine/arginine-rich splicing factor 3. Once considered to be a Western disease, the incidence of CD has rapidly increased in East Asian countries, such as Japan, Korea, and Hong Kong, while plateauing in the West[5,6] Both intestinal BD and CD often present similar gastrointestinal and extraintestinal manifestations, as well as endoscopic findings. Proteomic analysis is a promising technology that is a powerful tool for identifying biomarkers to help diagnose and choose personalized treatment It allows high-throughput study of protein expression with high accuracy, sensitivity, and repeatability, and it enables the identification of molecular mechanisms that are responsible for the development of a specific d isease[11,12]. Since gel-free proteomic approaches have several advantages compared to gel-based approaches, for identifying membrane-bound and/or glycosylated large proteins (e.g., mucins)[15], we used gel-free approaches to analyze intestinal BD proteomes in comparison with CD proteomes
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
